Scientific illustration of Ascletis’ ASC30 once-daily oral small-molecule GLP-1 receptor agonist, showing GLP-1 receptor binding, appetite and gastrointestinal effects, weight reduction and global Phase III clinical development.

Ascletis Doses First Participant in Global Phase III Program of Oral GLP-1 Drug ASC30

August 30, 2026 8 Min Read

Ascletis Pharma has dosed the first participant in its global Phase III AURORA clinical program evaluating ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management, launching a roughly 4,600-patient registrational program across the United States, Europe and Canada.

HONG KONG, August 30, 2026 — Ascletis Pharma (HKEX: 1672) has announced that the first participant has been dosed in the global Phase III clinical program for ASC30, moving the Chinese biotech’s internally discovered oral GLP-1 receptor agonist into pivotal development for obesity and overweight.

The program consists of two randomized, double-blind, placebo-controlled Phase III trials — AURORA-1 (NCT07743463) and AURORA-2 (NCT07743450) — that are expected to enroll approximately 4,600 participants across clinical sites in the United States, Europe and Canada. (ascletis.com, prnewswire.com)

Both studies will evaluate three maintenance doses of once-daily oral ASC30 — 20 mg, 40 mg and 60 mg — over 72 weeks.

Ascletis expects topline results from the global Phase III program in the third quarter of 2028, followed by a planned U.S. FDA New Drug Application (NDA) by the end of 2028 and a European Medicines Agency Marketing Authorisation Application (MAA) in early 2029. (prnewswire.com)

If successful, ASC30 could establish Ascletis as a significant global competitor in the rapidly expanding market for oral obesity medicines.

ASC30 Moves Into Global Pivotal Development

ASC30 is a proprietary, investigational small-molecule GLP-1 receptor (GLP-1R) agonist discovered and developed internally by Ascletis.

Unlike peptide GLP-1 drugs that are commonly administered by injection, the ASC30 formulation now entering Phase III is a conventional once-daily oral tablet.

Ascletis has described ASC30 as a GLP-1R biased agonist designed without β-arrestin recruitment. Earlier preclinical and clinical work supported oral once-daily administration, while Ascletis has separately explored long-acting injectable formulations of the same molecule. (ascletis.com)

The oral program has now become one of the most advanced assets in Ascletis’s expanding metabolic-disease portfolio.

Two AURORA Phase III Trials, Around 4,600 Participants

The global Phase III program has been structured around two complementary patient populations.

Trial	Population	Approx. Enrollment	Treatment	Duration
AURORA-1	Obesity or overweight with weight-related comorbidity, without type 2 diabetes	~3,000	ASC30 20, 40 or 60 mg vs. placebo	72 weeks
AURORA-2	Obesity or overweight with type 2 diabetes	~1,560	ASC30 20, 40 or 60 mg vs. placebo	72 weeks
Combined	Global obesity/overweight population	~4,600	Once-daily oral ASC30	72 weeks

AURORA-1 is registered as NCT07743463 and is expected to enroll approximately 3,003 adults. The study is evaluating long-term efficacy, safety and tolerability in adults with obesity or overweight and at least one weight-related comorbidity, but without type 2 diabetes. (clinicaltrialsfind.com)

AURORA-2, registered as NCT07743450, is expected to enroll approximately 1,560 adults with obesity or overweight who also have type 2 diabetes. (centerwatch.com)

The combined enrollment makes AURORA by far the largest clinical program undertaken for ASC30 to date.

Three Maintenance Doses Could Define Dose-Response Profile

Both pivotal trials will evaluate 20 mg, 40 mg and 60 mg maintenance doses.

Ascletis has designed different titration periods for the three doses:

20 mg: 12-week titration;
40 mg: 16-week titration; and
60 mg: 20-week titration.

The gradual dose escalation is intended to improve gastrointestinal tolerability, an important consideration across the GLP-1 drug class. (ascletis.com)

This strategy builds directly on Ascletis’s earlier Phase I and Phase II experience, which suggested that lower starting doses and slower titration could help control gastrointestinal adverse events while maintaining weight-loss efficacy.

Phase II Produced Up to 7.7% Placebo-Adjusted Weight Loss at 13 Weeks

The decision to advance ASC30 into Phase III was supported by positive results from a 13-week U.S. Phase II study in participants with obesity.

ASC30 demonstrated a dose-dependent effect on body weight.

ASC30 Dose	Placebo-Adjusted Mean Weight Reduction at Week 13
20 mg	5.4%
40 mg	7.0%
60 mg	7.7%

Importantly, Ascletis reported no weight-loss plateau at Week 13, suggesting that additional weight reduction might occur with longer treatment. (ascletis.com)

Among participants receiving 60 mg ASC30, 80% lost at least 5% of their baseline body weight, compared with 4.2% of placebo recipients.

Meanwhile, 45% of patients receiving 60 mg lost at least 7% of body weight, versus 4.2% with placebo. (ascletis.com)

The study population had a mean baseline weight of approximately 107.3 kg and mean BMI of 38.6 kg/m².

The Phase II study also showed improvements in several cardiovascular risk markers, including total cholesterol, LDL cholesterol, triglycerides and systolic and diastolic blood pressure. (ascletis.com)

Ascletis presented the Phase II ASC30 results at the American Diabetes Association’s 86th Scientific Sessions in June 2026. Ascletis ASC30 research and ADA 2026 presentation

Earlier Phase I Data Established Proof of Concept

ASC30’s clinical development moved quickly following encouraging early-stage results.

In a U.S. Phase Ib multiple-ascending-dose study, once-daily ASC30 produced substantial weight reduction after only four weeks.

One titration regimen — escalating through 2 mg, 10 mg, 20 mg and 40 mg — produced a 6.3% mean reduction from baseline, compared with a 0.2% weight increase for placebo.

That translated into a 6.5% placebo-adjusted mean body-weight reduction after four weeks. (ascletis.com)

A slower 2 mg → 5 mg → 10 mg → 20 mg regimen produced a 4.5% placebo-adjusted reduction.

No serious adverse events or Grade 3 or higher adverse events were reported in those dosing groups. Most gastrointestinal adverse events were mild and short-lived, according to Ascletis. (ascletis.com)

Those findings helped establish the slower titration strategy subsequently incorporated into later development.

Why Oral Small-Molecule GLP-1 Drugs Matter

The GLP-1 market has been built primarily around injectable peptide drugs.

Small-molecule oral GLP-1 receptor agonists could potentially change the competitive landscape by offering several practical advantages.

Unlike peptides, small molecules may be manufactured using conventional chemical synthesis rather than peptide manufacturing infrastructure. Oral tablets can also eliminate needles, simplify distribution and potentially improve manufacturing scalability.

Most importantly, a convenient once-daily pill could appeal to patients reluctant to use chronic injectable therapies.

The commercial potential of this approach is no longer theoretical.

In April 2026, the U.S. FDA approved Eli Lilly and Company’s Foundayo (orforglipron), establishing the first approved oral small-molecule GLP-1 receptor agonist for chronic weight management. The drug can be taken once daily without food or water restrictions. (fda.gov)

That approval both validates the oral small-molecule GLP-1 modality and raises the competitive bar for ASC30.

Ascletis Targets Potential No. 2 Position Behind Orforglipron

Ascletis has explicitly stated that, if development and regulatory review proceed successfully, ASC30 has the potential to become the second oral small-molecule GLP-1 receptor agonist available in the U.S. and Europe. (prnewswire.com)

That is an ambitious target.

Lilly’s orforglipron has already established a substantial clinical and commercial lead. Its Phase III program demonstrated clinically meaningful weight loss over 72 weeks, leading to FDA approval in April 2026. (lilly.gcs-web.com)

ASC30 therefore will not need simply to demonstrate that an oral small-molecule GLP-1 works. It will increasingly need to establish a competitive profile based on some combination of:

weight-loss efficacy, gastrointestinal tolerability, dosing convenience, safety, manufacturing economics and pricing.

The 72-week AURORA studies should provide the first robust opportunity to determine how ASC30 performs over a treatment duration comparable with other late-stage obesity medicines.

Phase III Will Test Whether Early Weight Loss Persists

One of the most important unanswered questions surrounding ASC30 is the durability and ultimate magnitude of weight loss.

The Phase II study lasted only 13 weeks.

At the highest dose, placebo-adjusted weight loss reached 7.7%, with no plateau observed. That is encouraging, but short-duration studies cannot reliably predict the magnitude of weight reduction after a year or more of treatment. (ascletis.com)

AURORA-1 and AURORA-2 extend treatment to 72 weeks.

The studies therefore should answer several critical questions:

How much weight loss can ASC30 ultimately produce?

Does efficacy continue to increase beyond 13 weeks?

How well can patients tolerate the 40 mg and 60 mg doses over long-term treatment?

Does ASC30 maintain efficacy in patients with type 2 diabetes, a population that often experiences less weight loss than patients without diabetes?

The answers will largely determine ASC30’s eventual competitive position.

From Phase II to Phase III in Less Than a Year

The speed of the program is also notable.

Ascletis reported the 13-week Phase II results in late 2025, presented detailed data at ADA 2026 in June, announced initiation of the global Phase III program in early August, and has now confirmed dosing of the first participant.

The timeline illustrates the company’s effort to maintain momentum in an obesity market where several multinational and Chinese companies are racing to develop next-generation oral therapies.

Ascletis has also stated that it has sufficient cash resources to fund operations through 2029, including the anticipated ASC30 NDA and MAA submissions. (ascletis.com)

That is strategically significant because the roughly 4,600-patient AURORA program represents a major financial and operational commitment for a biotech of Ascletis’s size.

ASC30 Anchors a Broader Obesity Pipeline

ASC30 is increasingly the centerpiece of a broader metabolic pipeline being assembled by Ascletis.

The company is pursuing multiple oral and long-acting approaches to obesity rather than relying on a single GLP-1 asset.

Alongside ASC30, Ascletis has disclosed programs targeting additional metabolic pathways, including GLP-1/GIP, amylin and multi-agonist mechanisms.

The company has also explored long-acting injectable versions of ASC30, including formulations designed for much less frequent dosing than conventional GLP-1 therapies.

This gives Ascletis two parallel strategic opportunities: compete in the emerging oral obesity-drug market while developing longer-duration injectable therapies aimed at reducing injection frequency.

ASC30’s oral Phase III program, however, is now clearly the company’s most important near-term value driver.

A Critical Global Test for Ascletis

Dosing the first participant in AURORA marks a significant milestone not only for ASC30 but for Ascletis itself.

The company has moved an internally discovered Chinese small molecule from early clinical testing into a large, multinational Phase III obesity program spanning the United States, Europe and Canada.

The next two years will determine whether the strong early weight-loss signals observed over four and 13 weeks translate into durable efficacy over 72 weeks.

Several milestones now stand out:

Expected Milestone	Timing
AURORA-1 and AURORA-2 enrollment and treatment	2026–2028
Phase III topline results	Q3 2028
Planned U.S. FDA NDA submission	By end of 2028
Planned EMA MAA submission	Early 2029
Potential commercial launch	Subject to regulatory approval

If ASC30 reproduces its earlier efficacy while maintaining competitive gastrointestinal tolerability over 72 weeks, Ascletis could emerge as one of the relatively few Chinese biotechnology companies with a homegrown obesity medicine positioned for direct commercialization in major Western markets.

For now, however, the critical test has only just begun.

With the first participant dosed and approximately 4,600 patients targeted for enrollment, the AURORA Phase III program will provide the definitive test of whether ASC30 can translate promising early-stage weight loss into a globally competitive oral obesity therapy.

References

Tags: